Abstract
Tamoxifen, a prodrug used for adjuvant breast cancer therapy, requires conversion to the active metabolite endoxifen through CYP 2D6. We aimed to construct an algorithm to predict endoxifen concentrations based on a patient’s CYP 2D6 genotype, demographic factors, and co-medication use. Eighty-eight women enrolled in the UCSF TamGen II study and 81 women enrolled in a prospective study at Dana-Farber Cancer Institute were included in this analysis. All the women had been on tamoxifen for at least 3 months before blood collection. Demographic information included the patient’s age, race/ethnicity, body mass index (where available), and self-reported and measured medications and herbals that affect 2D6 activity. DNA was extracted and genotyped for 2D6 (Amplichip, Roche Diagnostics). An activity score was calculated based on genotypes and adjusted for use of medications known to inhibit 2D6. Serum was tested for tamoxifen and metabolite concentrations and for the presence of drugs by liquid chromatography/mass spectrometry. Univariate and multivariate regression analysis were computed for age, body mass index, ethnicity, and adjusted activity score to predict tamoxifen metabolite concentrations in the training data-set of UCSF patients, and the resulting algorithm was validated in the Dana-Farber patients. For the training set, the correlation coefficient (r 2) for log endoxifen and N-desmethyltamoxifen:endoxifen ratio to activity score, age, and race, were 0.520 and 0.659, respectively; 0.324 and 0.567 for the validation; and 0.396 and 0.615 for both the datasets combined. An algorithm that incorporates genotype and demographic variables can be used to predict endoxifen concentrations for women on tamoxifen therapy. If endoxifen levels are confirmed to be predictive of tamoxifen benefit, then this algorithm may be helpful to determine which women warrant endoxifen testing.
Similar content being viewed by others
Abbreviations
- CYP:
-
Cytochrome
- UCSF:
-
University of California, San Francisco
- ATAC:
-
Arimidex, Tamoxifen, Alone or in Combination
- BIG:
-
Breast International Group
- WHEL:
-
Women’s Healthy Eating and Living
- TamGEN:
-
Tamoxifen genetics
- PCR:
-
Polymerase chain reaction
- BMI:
-
Body mass index
References
Brauch H, Murdter TE, Eichelbaum M, Schwab M (2009) Pharmacogenomics of tamoxifen therapy. Clin Chem 55:1770–1782
Goetz MP, Know SK, Suman VJ et al (2006) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113–121
Schroth W, Goetz MP, Hamann U et al (2009) Association between CYP2D6 polymorphism and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429–1436
Lash TL, Lien EA, Sorensen HT, Hamilto-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet 10:825–833
Rae JM, Drury S, Hayes DF et al. (2010) Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial [abstract S1–7]. Abstract presented at: 33rd Annual San Antonio breast cancer symposium; San Antonio, TX, December 8–12, 2010. http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1093 Accessed 3 March 2011
Leyland-Jones B, Regan MM, Bouzk M et al. (2010) Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial [abstract S1–8]. Abstract presented at: 33rd Annual San Antonio breast cancer symposium; San Antonio, TX, December 8–12, 2010 http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_556 Accessed 3 March 2011
International Warfarin Pharmacogenetics Consortium (2009) Improved warfarin dosing with a global pharmacogenetic algorithm. N Engl J Med 360:753–764
Borges S, Desta Z, Jin Y et al (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50:450–458
Madlensky L, Natarajan L, Tchu S et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype and breast cancer outcomes. Clin Pharmacol Ther 89:718–725
Lorizio W, Beattie M, Tchu S et al (2011) Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med 3:64
Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74
Tchu S, Lynch K, Wu AHB (2011) Therapeutic drug monitoring of tamoxifen using LC-MS/MS. In: Langman LJ, Snozek CLH (eds) Methods in molecular biology—LC-MS in drug analysis. Springer, New York (in press)
Wu AHB, Gerona R, Armenian P et al (2011) Comprehensive drug testing using liquid chromatography-time-of-flight mass spectrometry for clinical toxicology. Clin Toxicol (submitted)
Package insert (2007) AmpliChip CYP450 test. Roche Molecular Systems, Branchburg, NJ
Borges S, Desta Z, Li L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61–74
Wu AHB, Babic N, Yeo JT (2009) Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. Personalized Med 6:315–327
Irvin WJ, Walko CM, Weck KE et al (2011) Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 29:3232–3239
Rae JM, Sikora MJ, Henry NL et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9:258–264
Lubitz SA, Scott SA, Rothlauf EB et al (2010) Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost 8:1018–1026
Brown RR, Bain R, Jordan VC (1983) Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation. J Chromatogr 272:351–358
Gurley BJ, Swain A, Hubbard MA et al (2008) Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effect of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort, and Echinacea. Mol Nutr Food Res 52:755–763
Murdter TE, Schroth W, Bacchus-Gerybadze L et al (2011) The German Tamoxifen and AI Clinicians Group. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of Phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708–717
Jaremko M, Kasai Y, Barginear MF et al (2010) Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry. Anal Chem 92:10186–10193
Conflict of interest
The authors have all declared no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wu, A.H.B., Lorizio, W., Tchu, S. et al. Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. Breast Cancer Res Treat 133, 677–683 (2012). https://doi.org/10.1007/s10549-012-1963-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-012-1963-2